Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy

Giulia Galli, Claudia Proto, Diego Signorelli, Martina Imbimbo, Roberto Ferrara, Arsela Prelaj, Alessandro De Toma, Monica Ganzinelli, Nicoletta Zilembo, Filippo De Braud, Marina C. Garassino, Giuseppe Lo Russo

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: A minority of patients gains advantage from immunotherapy (IO). Predictive variables of long-term benefit (LTB) are incompletely understood. Materials & methods: We retrospectively collected data about metastatic non-small-cell lung cancer patients treated with IO from April 2013 to July 2017. We defined LTB to IO as complete response (CR), partial response (PR) or disease stability as best response and maintaining it for ≥12 months. Results: Thirty-five of the 147 patients had LTB. More LTB patients than controls showed CR/PR as first and best response to IO. Only CR/PR as best response to IO retained association to LTB at multivariate analyses. Conclusion: Objective response appears as a central factor for LTB from IO.

Original languageEnglish
Pages (from-to)2743-2757
Number of pages15
JournalFuture Oncology
Volume15
Issue number23
DOIs
Publication statusPublished - Aug 2019

Keywords

  • disease response
  • immunotherapy
  • long-term benefit
  • non-small-cell lung cancer
  • survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy'. Together they form a unique fingerprint.

Cite this